A ‘built-in genetic circuit’ could fight cancer by starving tumors of oxygen

A ‘built-in genetic circuit’ could fight cancer by starving tumors of oxygen By Luke Dormehl — November 25, 2016 2:02 PM - - See Original Here Imagine having cells in your body that can actively repel cancer in a way that makes it theoretically impossible for you to suffer from it. Researchers at the ’s University…
Continue Reading »

Metastatic rhabdomyosarcoma initially diagnosed on the bone marrow

Metastatic rhabdomyosarcoma initially diagnosed on the bone marrow Andrés E. Quesada and Rashmi Kanagal-Shamanna | Blood 2016 128:2189; | See Original Here A 15-year-old boy presented with a rapid-onset right-sided facial mass, thrombocytopenia (114 × 109/L), and elevated serum lactate dehydrogenase. A computed tomography scan demonstrated a maxillary sinus and nasopharyngeal mass with extensive cervical lymphadenopathy. Bone…
Continue Reading »

Novel microRNA Regulatory Network Has Important Therapeutic Implications in Rhabdomyosarcoma

Novel microRNA Regulatory Network Has Important Therapeutic Implications in Rhabdomyosarcoma Interview with: Riccardo Taulli, PhD Assistant Professor of Biochemistry Dept. of Oncology, University of Turin Via Santena 5, 10126 Torino, Italy : What is the background for this study? Response: Rhabdomyosarcoma is a muscle-derived pediatric cancer for which therapeutic options have not improved significantly over…
Continue Reading »

Registration is open for the Focus On Rhabdo Webinar – Dr. Noah Berlow – Nov 6th at 2PM Eastern

Save the Date - Sunday, November 6, 2016 - Focus On Rhabdo Webinar Featuring Dr. Noah Berlow of the Children's Cancer Therapy Development Institute - cc-TDI. His presentation will cover the computational and biological aspects of cc-TDI's approach to personalized cancer therapy design. This approach is based on integrating anti-cancer drug screening and genomics data using a…
Continue Reading »

Focus On Rhabdo Webinar – Nov 6, 2016 – Dr. Noah Berlow of cc-TDI

  Save the Date - Sunday, November 6, 2016 - Focus On Rhabdo Webinar Featuring Dr. Noah Berlow of the Children's Cancer Therapy Development Institute - cc-TDI. His presentation will cover the computational and biological aspects of cc-TDI's approach to personalized cancer therapy design. This approach is based on integrating anti-cancer drug screening and genomics data using…
Continue Reading »

Researchers develop algorithm to find precise cancer treatments

Researchers develop algorithm to find precise cancer treatments August 10, 2016 | eCancerNews | See Original Here University of Hawai'i Cancer Center researchers developed a computational algorithm to analyse "Big Data" obtained from tumour samples to better understand and treat cancer. "A growing problem in cancer research is figuring out how to analyse the many…
Continue Reading »

Killer T cells recognize cancer in pre-clinical tumors, but are silenced as tumor develops

Killer T cells recognize cancer in pre-clinical tumors, but are silenced as tumor develops Date: August 9, 2016 | Source: Fred Hutchinson Cancer Research Center | ScienceDaily | See Original Here [COMMENT: Certainly more work is needed.  Let's hope it is pushed to the forefront. (Alan)} Summary: In a tumor's pre-clinical stages, certain immune cells can recognize changes that make…
Continue Reading »

Selinexor Shows Promise in Phase I Sarcoma Trial

Selinexor Shows Promise in Phase I Sarcoma Trial Dave Levitan | July 26, 2016 | CancerNetwork | See Original Here A phase I trial of selinexor, an inhibitor of the nuclear export compound exportin 1 (XPO1), found the drug was reasonably well tolerated and showed some activity in patients with advanced soft-tissue or bone sarcoma…
Continue Reading »

Fusion-Negative Sarcoma Survivors Have Increased Risk of Second Malignancies

Fusion-Negative Sarcoma Survivors Have Increased Risk of Second Malignancies Dave Levitan | August 4, 2016 | CancerNetwork | See Original Here Survivors of fusion-negative (F−) sarcomas have a higher risk of developing a second malignant neoplasm than those who had fusion-positive (F+) sarcomas, according to a new study, which could offer guidance on surveillance of these…
Continue Reading »
Skip to toolbar